News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|October 14, 2024

Optimizing Vitiligo Management: Key Takeaways on Treatment Cycling and Ruxolitinib Use

Author(s)Terry Faleye, MPAS, PA-C

Panelists discuss how treatment cycling strategies and optimal use of ruxolitinib can enhance the management of vitiligo, providing key takeaways for clinical practice.

Episodes in this series

1 KOL is featured in this series.

EP. 1 Vitiligo Insights: Case-Based Discussion on Delayed Treatment, Psychosocial Impact, and Evolving Approaches for SOC Patients

1 KOL is featured in this series.

EP. 2 Case-Based Discussion on Adherence, Adjunctive Therapy, and Simplifying Complex Regimens for Patients With Vitiligo

1 KOL is featured in this series.

EP. 3 Exploring Phototherapy, Combination Therapy, and Patient-Centered Approaches to Improve QOL for Patients with Vitiligo

1 KOL is featured in this series.

EP. 4 Expert Insights Into Handling Treatment Challenges and Site-Specific Concerns in Vitiligo Management

1 KOL is featured in this series.

EP. 5 Exploring Efficacy, Novel Mechanisms, and Patient Engagement in the Management of Vitiligo

1 KOL is featured in this series.

EP. 6 Vitiligo Treatment Paradigms: Clinician Experiences with Topical Ruxolitinib and Access Challenges

1 KOL is featured in this series.

EP. 7 Optimizing Vitiligo Management: Key Takeaways on Treatment Cycling and Ruxolitinib Use

EP. 8 Improving Care and Innovations in Vitiligo and Atopic Dermatitis: Part 1

EP. 8 Improving Care and Innovations in Vitiligo and Atopic Dermatitis: Part 1

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Site-Specific MED Variability Guides 308-nm Excimer Laser Dosing

ByMaddi Hebebrand, MC, Associate Editor

December 10th 2025

Impaired HRQoL and High Psychological Comorbidity Observed in Japanese Vitiligo Patients

ByMarie Bosslett, Assistant Editor

December 10th 2025

AI at the Bedside: How Automated Solutions are Transforming Vitiligo Management

ByMarie Bosslett, Assistant Editor

December 9th 2025

Clear Communication Helps Reduce Patient Concerns About Boxed Warnings

ByMichael Lewitt, MD ,Maddi Hebebrand, MC, Associate Editor

November 25th 2025

Clinical Pearls for Management of Pediatric Atopic Dermatitis With Topicals

ByPeter Lio, MD,Jeff Yu, MD, MS

November 21st 2025

Latest CME

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Transformative Advances This Year and Beyond

FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol

Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control

The SkinCARE Questionnaire: Assessing the Psychological Dimensions of Skin Health Beyond Disease

Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population

© 2025 MJH Life Sciences^®

All rights reserved.